Menu
Synergy in Action

6th Annual Scientific Meeting

plus 2010 National Mental Health Research-to-Policy Forum
22 – 24 February, 2010   //   Washington DC, USA

Poster Awardees

Do Recruitment Sources Impact Study Outcome: Assessment by Computer and Site-Based Raters
B Kasuba, S Edman
“Reporting Adverse Event Data From Clinical Trials of Antipsychotic Agents”
I Turkoz
Placebo Response Assessed by Site and Blinded Remote Centralized Raters in a GAD Trial
J Williams
All poster abstracts are available for public viewing. Link found at end of Day 1.

Day 1 (22 February 2010)

President’s Welcome L Alphs

video

SESSION 1: New Approaches to Assessing the Safety of Marketed Drugs – FDA, Industry and Academic Perspectives

SESSION SUMMARY

 

Chairs:

S Marder
M Tohen

Approaches to Safety Assessment: A Pharmacoepidemiological Perspective P Wang*
Current Approaches to Pharmaceutical Benefit-Risk Assessment B Levitan

slides slides

video

Approaches to Marketing Medical Product Safety Assessment: An FDA Perspective A McMahon (Racoosin)

slides slides

Panel and General Discussion C Bowden

video

 

SESSION 2: Translational and Cultural Adaptation of Key Outcome Measures in International CNS Trials

SESSION SUMMARY

 

Chairs:

A Kalali
R Keefe

The Current Reality of Outcome Measures in International Clinical Trials: Should We Be Doing Things Differently? A Kalali

slides slides

video

Challenges and Best Practices in Training and Monitoring Measurement of Psychopathology in Linguistically and Culturally Diverse Settings D Daniel

slides slides

video

 

Translating and Implementing Measures of Neurocognition in Eastern Europe and Asia R Keefe

slides slides

video

Cultural Considerations of Functional Outcomes in Chinese and Other Cultures P Harvey

slides slides

video

 

Cultural Aspects of Outcome Measures – European and US Regulatory Viewpoints K Broich

video

T Laughren

video

 

Discussant R Anand

slides slides

video

Poster Session View All Poster Abstracts

 

Day 2 (23 February 2010)

ISCTM 2010 National Mental Health Research-to-Policy Forum: The Role of Comparative Effectiveness Research in Future Mental Health Policy Decision Making

 

Chairs:

R Ferziger
R Manderscheid

SESSION 3a: The Role of CER in Future Mental Health Policy Decision Making

SESSION SUMMARY

Chair:

D Steinwachs

CER 2010: Overview and Critical Review of the Current Science and Politics of Comparative Effectiveness B Luce

slides slides

video

  Keynote Address: The Role of CER in Future Mental Health Policy Decision Making M Rawlins

slides slides

video

  Discussant J Slutsky

slides slides

 

  Panel Discussion M Schoenbaum
D Shern

video

Relating the Science of CER to Mental Health Policy and Clinical Care

 

Chair:

B Druss

Locations, Populations and the Generalizability of Data for Policy Decisions in Mental Health R Frank*

video

Discussant M Rawlins

slides slides

 

Panel Discussion J Parks
K Broich

D Jarvis

video

Hitchhikers Guide to System Comparative Effectiveness S Leff

slides slides

video

 

Panel Discussion video

 

   
SESSION 3b: Comparative Effectiveness Trials in CNS Disorders: Rationale, Elements and Challenges

SESSION SUMMARY

Chairs:

N Schooler
C Bowden

  What Constitutes Comparative Effectiveness Research? NIH and Inferential Perspectives C Bowden

slides slides

video

  Key Issues in CER for Design and Analysis T Ten Have

slides slides

video

  Goals and Strategies of the NIMH Recovery After an Initial Schizophrenia Episode (RAISE) Initiative B Heinssen

slides slides

video

 

  The NIMH RAISE Initiative. Two Parallel Approaches to a CER Question:  
  Case Study I N Schooler

slides slides

video

 

  Case Study II L Dixon

slides slides

video

(H Goldman)

  Academic Discussant D Meltzer

video

  NICE Discussant M Rawlins

slides slides

video

  Panel and Participants Discussion  
  Summary  
Dinner Symposium: Industry/Academic Relationships: Continuing Collaboration in an Era of Evolving Standards

SUMMARY

Chairs:

R Keefe
N Schooler

  Principled Research in the Face of Conflicts of Interest R McKinney

slides slides

video

Day 3 (24 February 2010)

SESSION 4: Clinical Trials in the Prodromal Phase of Alzheimer’s Disease-Methodological Challenges and Clinical Outcomes

SUMMARY OF SESSION

 

Chairs:

G Garibaldi

M Davidson

Challenges Faced when Identifying and Providing Prodromal Disease treatments: The Problems of Preserving Wellness M Davidson

slides slides

video

Keynote Address: “Antecedent Biomarkers in Prodromal Alzheimer’s Disease – Now is the Time” J Morris

slides slides

video

Clinical Correlations with Postmortem Findings: Clues to Identifying the Prodrome for AD-Age Matters V Haroutunian

slides slides

video

How Recent Developments in Biomarkers Have Changed Clinical Trials Design-from the Perspective of the Trialist R Schindler

slides slides

video

 

Neuroroimaging as a Marker for Prodromal Treatment: Evidence, Value and Limitations M Cantillon*

 

Clinical Trials in Prodromal AD: An Industry Viewpoint R Anand

slides slides

video

 

Prodromal Alzheimer’s Disease-EU Regulatory Point of View K Broich

slides slides

Roundtable Discussion video
Adjourn  
* Presentation materials have not been released for posting.